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Abstract
Background: The present study represents the first attempt to functionally characterize two
common single nucleotide polymorphisms (SNPs) in the 3'untranslated regions (3'UTRs) of
estrogen receptor β (ERβ), focusing on the differences between alleles with regard to mRNA
stability and translatability. These two ERβ SNPs have been investigated for association with disease
in a large number of reports.
Results:  Here we examined allelic expression in breast tumor samples from heterozygous
individuals. A significant difference in mRNA levels of the two alleles was observed for one of the
SNPs. A cell model system was employed to further investigate potential molecular effects of the
two SNPs. We used a modified plasmid, containing the ERβ promoter and ERβ 3'UTRs which
include the different alleles of investigated SNPs. Quantitative Real-Time PCR was used to
determine mRNA levels after inhibition of transcription by actinomycin D, and a luciferase assay
was used to determine protein levels. The obtained results suggested that there was no difference
in mRNA stability or translatability between the alleles of investigated SNPs.
Conclusion: Our results indicate that observed associations between ERβ 3'UTR SNPs and
disease susceptibility are due to linkage disequilibrium with another gene variant, rather than the
variant itself being the susceptibility factor.
Background
The steroid hormone estradiol-17β exerts its functions
through binding to estrogen receptors (ERs), ERα and
ERβ. The ERs belong to the nuclear receptor superfamily,
a family of ligand-regulated transcription factors [1]. Both
receptors, when ligand-activated, modulate gene expres-
sion and subsequently trigger a broad repertoire of physi-
ological responses.
Estrogen signaling is involved in the regulation of devel-
opment, growth and function of diverse systems, includ-
ing human reproductive organs, mammary glands and
skeletal and nervous systems. Aberrations in estrogen sig-
naling have been proposed to be associated with several
diseases, such as breast, endometrial, and ovarian cancers,
osteoporosis, eating disorders and depression [2-4].
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Five ERβ isoforms, designated ERβ1-5, have been reported
in humans [5]. Among them, the presence of a corre-
sponding protein has been clearly demonstrated only for
ERβ1 (wild type) and ERβ2. The ERβ1-5 transcripts have
unique sequences in place of exon 8, and thus different
3'untranslated region (3'UTRs). Single nucleotide poly-
morphisms (SNPs) in 3'UTRs have been identified only
for ERβ1 and ERβ2. It has been shown that both ERβ1 and
ERβ2 transcripts are regulated by the same promoter, des-
ignated as promoter 0N [6]. Promoter 0N was first
described by Li et al. [7], and shown to contain both TATA
box and initiator element (Inr) and putative binding sites
for transcription factors AP-1, AML-1a and Oct-1.
Two SNPs in the ERβ gene have been studied for associa-
tion with a number of diseases. They are referred to as
rs4986938 and rs928554 [8]. rs4986938 is a G↔A transi-
tion in exon 8, corresponding to ERβ1 3'UTR. rs928554 is
a G↔A transition in exon 9, corresponding to ERβ2 3'UTR
(Figure 1A). The distribution of these SNPs in some
human populations is shown in Table 1 and Table 2.
rs4986938 was first reported in a study on anorexia ner-
vosa by Rosencrantz et al. [9]. rs928554 was first
described by Nilsson et al., and both this SNP and
rs4986938 were found to be associated with bulimia [10].
In another study, both SNPs have been associated with
increased homocysteine levels [11]. Furthermore,
rs4986938 has been associated with osteoporosis in
women [12], ovulatory dysfunctions [13,14], Parkinson's
[15] and Grave's disease [16]. In one study, rs928554 was
associated with preeclampsia [17]. The allele frequencies
of these SNPs in some case control studies are presented
in Table 3. This table shows that different alleles are asso-
ciated with the highest disease incidence for different dis-
eases.
Studies of associations between these polymorphisms and
breast cancer risk indicate that they do not have an effect
per se [18-21]. However, association is found for haplo-
types which contain either both SNPs [19,21] or
rs4986938 solely [22].
3'UTRs are regulatory elements which can control protein
expression, primarily through effects on mRNA stability
but also through transcript translatability [23,24]. 3'UTRs
control poly(A) tail length either through polyadenyla-
tion (due to the presence of polyadenylation AU signals)
Locations of the two SNPs in ERβ 3'UTRs and reporter constructs used in transient transfection assays Figure 1
Locations of the two SNPs in ERβ 3'UTRs and reporter constructs used in transient transfection assays. A. 
rs4986938 is positioned in the 3'UTR of exon 8 and rs928554 in the 3'UTR exon 9. Exons are represented as shaded boxes, 
3'UTRs as white boxes, and introns as connecting lines. Exon 9 is an alternatively spliced last exon (represented as a dashed 
line), which gives rise to the ERβ variant ERβ2. B. Luciferase reporter constructs used in transient transfection assays were 
generated from a promoterless PGL3 basic plasmid. The ERβ promoter was introduced using restriction enzymes MluI and 
XhoI. XbaI and BamHI were used to replace the SV40 poly(A) signal with ERβ 3'UTR sequences.
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or deadenylation (e.g. binding of the PUF proteins) [25].
It has been reported that poly(A) tails correlate with trans-
lation, by poly(A) binding proteins interacting with trans-
lation factors at the 5' cap site. In most cases, long poly(A)
tails are associated with induction and short poly(A) tails
with repression of translation [24]. Loss of the poly(A) tail
is thought to promote mRNA degradation by facilitating
attack by both the exosome complex [26] and the decap-
ping complex [27]. However to our knowledge, no studies
have been published regarding mechanisms how SNPs
regulate mRNA stability and/or translatability.
Recent studies show that 3'UTRs contain targets for micro
RNAs (miRNAs) [28]. miRNAs are short endogenous
RNAs (~ 23 nt) that play important gene-regulatory roles
by pairing to the mRNAs of protein-coding genes to direct
their posttranscriptional repression, suggesting an addi-
tional mechanism for 3'UTR-controlled protein expres-
sion.
In this study, we first examined whether ERβ mRNAs, cor-
responding to the different investigated alleles, were
expressed at equal levels in breast tumor samples from
heterozygous individuals. Both ERβ variants are expressed
at significant amounts in breast tissue [29,30], which
makes it a good system to study endogenous expression of
ERβ mRNA. It is also generally acknowledged that ERβ has
an important role in the development of this disease [31].
Next, we used an in vitro system to investigate if different
alleles of the two commonly assayed SNPs in the ERβ
3'UTRs display differences in transcript stability or trans-
latability, thus providing a molecular explanation for the
observed disease associations.
Table 1: Frequency of rs4986938 in selected studies
Studied populations Sample size Allele frequency (%)* Study
GA
Caucasians 567 62.0 38.0 Westberg et al. [15]
Caucasians 1376 65.8 34.2 Kisiel et al. [16]
Caucasians 457 68.3 31.7 Forsti et al. [18]
Caucasians 628 65.0 35.0 Maguire et al. [19]
Caucasians 1107 62.0 38.0 Nilsson et al. [39]
Caucasians 1702 63.0 37.0 Ichikawa et al. [40]
Caucasians 862 62.0 38.0 Rexrode et al. [43]
Asians 526 86.5 13.5 Lee et al. [41]
Asians 776 86.0 14.0 Iwasaki et al. [44]
South Americans 758 67.0 33.0 Iwasaki et al. [44]
* Includes cases and controls
Table 2: Frequency of rs928554 in selected studies
Studied populations Sample size Allele frequency (%)* Study
GA
Caucasians 723 43.0 57.0 Maguire et al. [19]
Caucasians 1107 44.0 56.0 Nilsson et al. [39]
Asians 244 38.6 61.4 Maruyama et al. [17]
Asians 747 38.0 62.0 JSPN [45]
* Includes cases and controlsBMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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Methods
Allelic expression assay
Primary breast tumor tissue samples from patients with
invasive ductal carcinoma and undergoing breast cancer
surgery were frozen in liquid nitrogen immediately after
resection and stored at -80°C until use.
Genomic DNA from these samples was extracted using
GenElute™ Mammalian Genomic DNA Miniprep Kit
(SIGMA). RNA was extracted using Invitrogen's TRIzol LS
Reagent protocol for mammalian tissues. 1 μg of total
RNA was treated with Invitrogen's DNase I (Amplification
Grade) to eliminate the remains of DNA, and then con-
verted into cDNA using Invitrogen's protocol for Super-
Script® III Reverse Transcriptase.
To amplify the 3'UTRs that contain the studied SNPs, in
both genomic DNA and cDNA, PCR was performed. The
basic PCR protocol for Invitrogen's Taq DNA Polymerase
was used, with specific primers: ERβ1-F (5'-TGCTGCT-
GGAGATGCTGAAT-3') and ERβ1-R (5'-TCACAC-
CGACTCCTGAGAGTTG-3') for ERβ1 3'UTR, and ERβ2-F
(5'-GGGCAGAAAAGGCCTCTCA-3') and ERβ2-R (5'-
GAAGCCTCAGCTTTCTACATTGG-3') for ERβ2 3'UTR.
The amplified fragments were sequenced on Applied Bio-
systems' 3730 × l DNA Analyzer in Macrogen DNA
Sequencing Service [32].
Peak heights from sequencing reactions of genomic DNA
and cDNA were measured for each allele for the two SNPs.
Twenty samples were analyzed, and for each SNP under
investigation five showed to be heterozygotes, i.e. inform-
ative for the assay. For each sample and SNP, the relative
height of the peak for the cDNA versus the genomic DNA
was determined for a particular allele.
ERβ-Promoter-Luciferase-3'UTR-reporter constructs
Plasmid constructs were generated by cloning the ERβ
promoter and different ERβ 3'UTR sequences into a pro-
moterless PGL3 basic plasmid (Promega, Madison, W1).
A 1081 bp fragment of ERβ promoter 0N was amplified
from human genomic DNA (Roche), using Expand Long
Template PCR System (Roche, 150 U; recommended for
fragments longer than 1 kb) and specific forward (5'-TAT-
TACGCGTTCCTGCTGGGGTGGGTGAG-3') and reverse
primers (5'-TTATCTCGAGCGAAGGGGCGCTTACCTT-
3'). The primers were designed to incorporate restriction
sites for enzymes MluI and XhoI (marked bold in the
primer sequences), respectively. The promoterless PGL3
basic plasmid and the amplified fragment were digested
with MluI and XhoI. The amplified fragment was inserted
into the MluI/XhoI restriction sites of PGL3 basic, creating
plasmid ERβpromPGL3 (Figure 1B).
A 933 bp fragment of ERβ exon 8, corresponding to ERβ1
3'UTR, was amplified from human genomic DNA
(Roche), using Invitrogen's Platinum® Taq DNA Polymer-
ase protocol (5 U/μl), and forward (5'-TATTTCTAGAG-
CAGCCCGGCAGAGGACAG-3') and reverse primers (5'-
TTATGGATCCCCACATTGCCCCAGGGAAACACT-3'),
containing restriction sites for enzymes XbaI and BamHI
(marked bold in the primer sequences), respectively. The
ERβpromPGL3 plasmid and the ERβ1 3'UTR fragment
were digested with XbaI and BamHI. The ERβ1 3'UTR
fragment was inserted into the XbaI/BamHI restriction
sites of the ERβpromPGL3 plasmid, replacing the SV40
poly(A) signal, and creating plasmid
ERβpromPGL3ERβ1UTR.
A 1380 bp fragment of ERβ exon 9, corresponding to ERβ2
3'UTR was amplified from human genomic DNA (Roche),
using Roche's Expand Long Template PCR System (same
protocol as above), and forward (5'-TATTTCTAGA-
GAAAAGGCCTCTCAAACACTC-3') and reverse primers
Table 3: Allele frequencies of rs4986938 and rs928554 in cases versus controls
SNP Allele Disease Cases (%) Controls (%) Study
rs4986938 A ovulatory dysfunctions 25.8 10.3 Sundarrajan C et al. [13]
rs4986938 G Parkinson's disease 75.0 60.7 Westberg et al. [15]
rs4986938 A Grave's disease 38.0 32.7 Kisiel et al. [16]
rs4986938 A vascular dementia 51.0 38.0 Dresner-Pollak et al. [46]
rs4986938 G bulimia 43.0 26.0 Nilsson et al. [10]
rs928554 G 61.0 43.0
rs928554 A preeclampsia 71.3 60.8 Maruyama et al. [17]BMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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(5'-TTATGGATCCTAAATGCCAAACTACCGACTT-3'),
containing restriction sites for enzymes XbaI and BamHI
(marked bold in the primer sequences), respectively. The
amplified fragment was inserted into the ERβpromPGL3
plasmid (same as above), creating plasmid
ERβpromPGL3ERβ2UTR (Figure 1B).
Both amplified and cloned fragments contain the G nucle-
otide at the respective SNP positions. Mutagenesis was
performed in order to generate the corresponding A alle-
les, using the QuikChange® Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, California) and two primer sets:
ERβ1MutF (5'-GCCCACAGAGGTCACAAGCTGAAGCGT-
GAACTC-3') and ERβ1MutR (5'-GAGTTCACGCT-
TCAGCTTGTGACCTCTGTGGGC-3') for ERβ1 3'UTR, and
ERβ2MutF (5'-CAATGATCCCAGAGGGAAATTGAAGT-
GAAAATGTTACCC-3') and ERβ2MutR (5'-
GGGTAACATTTTCACTTCAATTTCCCTCTGGGAT-
CATTG-3') for ERβ2 3'UTR. The final products were four
different constructs, two for the each studied SNP:
ERβpromPGL3ERβ1UTR-G and
ERβpromPGL3ERβ1UTR-A for rs4986938, and
ERβpromPGL3ERβ2UTR-G and
ERβpromPGL3ERβ2UTR-A for rs928554. The sequences
of each pair of constructs differed only in the SNP under
investigation. The sequences of all constructs were verified
by DNA sequencing.
Transient transfection assays
Luciferase activity was measured in three human cell lines
- human fetal kidney HEK293 cells, cervical cancer HeLa
cells and breast adenocarcinoma MCF7 cells. HEK293 and
HeLa represent ER-negative cell lines [33,34], whereas
MCF7 is an ER-positive cell line. The cells were seeded
into 24-well plates (70% confluence) and co-transfected
with the constructs incorporating different ERβ 3'UTRs
(0.8  μg/well) and pRL-TK (Renilla plasmid, Promega,
0.02 μg/well), as internal control, using Lipofectamine
2000 (Invitrogen). Cells were harvested 24 h after trans-
fection, and the activities of Firefly and Renilla luciferases
were measured by the Dual Luciferase Reporter Assay Sys-
tem (Promega), using a Berthold FB12 Luminometer.
mRNA stability assay
The assay was performed on the HEK293 cell line. The
cells were maintained in 50% of Dulbecco's modified
Eagle's medium (Gibco), supplemented with 10% fetal
bovine serum (Saveen Werner AB), 1% penicillin-strepto-
mycin (Gibco), and 50% F12 Nutrient Mixture with L-
glutamine (Gibco), at 37°C in 5% CO2. Cells were trans-
fected with a total amount of 10 μg DNA at 90-95% con-
fluence in 10-cm dishes, using Lipofectamine 2000
(Invitrogen). At the end of transfection (4-6 h after Lipo-
fectamine treatment), cells were split into 6-well plates.
Twenty-four hours later, cells were treated with 1 μg/ml
actinomycin D (Sigma) [35] to suppress transcription.
Cells were harvested 0 and 24 h after actinomycin D treat-
ment. Total RNA was extracted using the RNeasy kit (Inv-
itrogen). mRNA levels were assayed using the SYBRGreen
PCR master mix (Applied Biosystems), with specific for-
ward (5'-ATCCGGAAGCGACCAACG-3') and reverse
primers (5'-CGGTAAGACCTTTCGGTACTTC-3'), which
target the Luciferase part of the Luciferase-ERβ3'UTR
hybrid constructs. 18S rRNA levels, used for normaliza-
tion, were measured using the Universal TaqMan PCR
Master Mix and 20 × 18S Target Primers and Probe (all
from Applied Biosystems). All Real-Time PCR experi-
ments were performed on a 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems).
Results
mRNA levels of endogenous ERβ alleles differ in 
heterozygous carriers for rs4986938, but not in 
heterozygous carriers for rs928554
To study a possible variation in allelic expression of
endogenous transcripts in human tissues, we performed
an allelic expression assay. In this assay, the relative
mRNA levels of two alleles are determined by cDNA
sequencing, and corrected for any difference in sequenc-
ing efficiency by normalizing with the sequence of
genomic DNA from the same individuals [36]. A differ-
ence in relative mRNA levels for two alleles shows that the
alleles differ with regard to mRNA levels, which could be
the result of differences in transcription or mRNA stabil-
ity. Figure 2 shows that there is a significant difference in
allelic expression of rs4986938, but not of rs928554.
ERβ 3'UTR alleles display similar luciferase activities and 
mRNA stability
To study molecular effects of the different alleles of the
3'UTRs, we generated four plasmids with different alleles
at investigated SNP positions. The created plasmids con-
tained the ERβ promoter, which regulates the expression
of the reporter luciferase gene fused to 3'UTRs from ERβ1
or ERβ2, respectively (Figure 1B). A similar assay was suc-
cessfully used in previous studies [35,37]. This assay
would capture any differences in mRNA stability and
translatability. The luciferase activities of all constructs
were measured in three different cell lines.
The luciferase activity of the plasmid ERβpromPGL3,
which carries the ERβ promoter and SV40 poly(A) signal,
was 9-fold higher comparing to the basic promoterless
PGL3 vector, suggesting that the included ERβ promoter
fragment is transcriptionally functional (Figure 3A). The
luciferase activities of the constructs including the ERβ
promoter and ERβ 3'UTR (ERβpromPGL3ERβUTR), were
about 30% of that of ERβpromPGL3, i.e. 3-fold higher
compared to the basic promoterless PGL3 vector. This is
expected since the SV40 poly(A) signal, which has highBMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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Allelic expression of ERβ 3'UTR SNPs in breast tumor samples Figure 2
Allelic expression of ERβ 3'UTR SNPs in breast tumor samples. A. Genomic DNA was sequenced in two independent 
assays. cDNA synthesis was performed twice and each cDNA was sequenced in two independent assays. For each sample and 
allele, the average peak heights from the four cDNA sequencing assays were normalized by the average peak heights from the 
two DNA sequencing assays. The results from five breast tumor samples heterozygous for each SNP are presented as relative 
allelic ratios for cDNA versus genomic DNA. Data are shown as mean ± SD, with allele G set to 100%. (a) ERβ1 3'UTR poly-
morphism (rs4986938 G↔A); (b) ERβ2 polymorphism (rs928554 G↔A).B. Representative examples of genomic DNA and 
mRNA sequencing. (a) ERβ1 3'UTR polymorphism (rs4986938); (b) ERβ2 3'UTR polymorphism (rs928554). Observe that for 
rs928554 G↔A, the bottom strand was sequenced therefore the DNA sequence reads C and T, respectively.BMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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translational potency, was replaced by the less potent
3'UTR.
There was no difference in luciferase activity between the
two alleles of ERβ1 3'UTR, in any of the three analyzed
cell lines, suggesting that the investigated ERβ1 3'UTR
SNP does not influence the mRNA stability and translata-
bility (Figure 3B). The same results were obtained for the
two alleles of ERβ2 3'UTR (Figure 3C).
In order to directly assay differences in mRNA stability
between ERβ 3'UTR alleles, we determined mRNA levels
in cells transfected with the different plasmids, after inhi-
bition of transcription with actinomycin D. Luciferase
constructs were transfected into HEK293 cells. Twenty-
four hours later, cells were treated with actinomycin D to
suppress transcription. mRNA levels at 0 and 24 h after
actinomycin D treatment were quantified by Real-Time
PCR. As shown in Figure 4, there was no difference in
mRNA levels, after inhibition of transcription with actin-
omycin D, between the two alleles, for the two analyzed
SNPs, suggesting that the investigated ERβ 3'UTR SNPs do
not influence the mRNA stability.
The predicted secondary structures of ERβ 3'UTR mRNAs 
suggest no differences in stability for the two alleles
We have investigated the secondary structures of ERβ
3'UTRs, using the Mfold web server for nucleic acid fold-
ing and hybridization prediction [38]. We compared ERβ
3'UTR sequences investigated in this study. Each of the
four analyzed ERβ 3'UTRs can form a number of second-
ary structures. Focusing on the structures with the lowest
free energy, i.e. the highest stability, no statistical differ-
ence was found between free energies for the G and A alle-
les of rs4986938, or for the G and A alleles of rs928554
(data not shown), supporting the results of the experi-
mental mRNA stability assay.
Discussion
SNPs that change the primary structure of the protein have
not been reported for ERβ. However, there are reports of
SNPs in promoter regions and 3'UTRs that could poten-
tially alter mRNA and protein levels. In this study, we
investigated the effects of two commonly studied SNPs,
rs4986938 and rs928554, in the 3'UTRs of ERβ, on mRNA
stability and translatability.
In order to study a possible variation in mRNA expression
of transcripts that include the different alleles of the two
SNPs, we have assayed mRNA levels in breast cancer sam-
ples which are heterozygotes for either of the two SNPs.
Significant difference in mRNA expression of the different
alleles was observed for the SNP in ERβ1 3'UTR, but not
for the SNP in ERβ2 3'UTR.
ERβ SNPs have been found to have a large amount of link-
age disequilibrium (LD) [21,39]. According to the HAP-
MAP haploblock structure, there are several additional
SNPs surrounding rs498693, which are in LD with
rs498693. Thus, we further investigated the molecular
effects of this SNP independent from other polymor-
phisms using an in vitro assay, where investigated ERβ
sequences are identical except for the SNP under investi-
gation. Future studies should aim at investigating the
effects of SNPs that are in LD with rs498693on mRNA lev-
els.
The two ERβ SNPs were analyzed in cell lines that express
or do not express endogenous ERs. We initially employed
an assay that simultaneously detects differences in mRNA
stability and translatability. This was complemented with
an assay that directly detects differences in mRNA stabil-
ity.
Luciferase reporter genes enable easy detection of changes
in transcript and protein stability. Furthermore, studying
isolated 3'UTRs in the context of a recombinant mRNA
avoids confounding effects of additional genetic varia-
tions when assaying endogenous alleles. Also, measuring
luciferase mRNA and protein as compared to ERβ mRNA
and protein, avoids potential problems of distinguishing
the molecules under investigation from any endogenous
mRNA and protein. Neither of the two in vitro assays
showed an effect of the different alleles of ERβ SNPs on
mRNA stability or translatability.
It is also of importance to note that, although there are
studies that associate these two SNPs with many different
disorders, there are also studies which do not provide
such evidence, even for the same disease. For example, our
study of a Swedish cohort associated both rs4986938 and
rs928554 with bulimia [10], while a study of a German
cohort did not [9]. An investigation of a Danish cohort of
postmenopausal women associated rs4986938 with bone
mineral density [12], whereas an American study of a
cohort of premenopausal women did not [40]. One study
associated rs4986938 with the risk of endometriosis in a
Korean population, but not in a Japanese population
[41].
There are many reasons which could explain the incon-
sistency between different studies in showing association
of, or lack of association of, SNPs in the ERβ 3'UTR with a
particular disease. In relation to the studies in this paper,
which suggest that the effects observed for the SNP in
ERβ1 3'UTR on mRNA levels could be due to LD with
another variant affecting mRNA levels, the haploblock
structure and thus the LD vary between different popula-
tions. If a SNP that has not been the focus of most studies
causes a phenotype, depending on the LD in a particularBMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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Figure 3
Relative luciferase activities of 3'UTR constructs assayed in three different cell lines. Relative luciferase activity is
calculated as the ratio of Firefly luciferase activity vs. Renilla luciferase activity. Three human cell lines (HEK293, HeLa and
MCF7) were co-transfected with 0.8 μg of the Firefly luciferase plasmids (PGL3 basic, ERβpromPGL3,
ERβpromPGL3ERβ1UTRG/A for rs4986938, ERβpromPGL3ERβ2UTRG/A for rs928554) and 0.02 μg Renilla luciferase plasmid
as internal control, at 70% confluence in 24-well plates. Cells were harvested 24 h after transfection, and the activities of Firefly
and Renilla luciferases were measured. Each measurement represents the average of three independent assays using independ-
ent plasmid preparations. Data are shown as mean ± SD. A. The luciferase activity of generated constructs in HEK293 cells, is
normalized to the basic PGL3 plasmid, whose activity is set to 100%. The same results were obtained in the two other cell lines
(data not shown); B. ERβ1 3'UTR polymorphism (rs4986938 G↔A);C. ERβ2 polymorphism (rs928554 G↔A). The luciferase
activity of allele G is set to 100%.BMC Genetics 2009, 10:55 http://www.biomedcentral.com/1471-2156/10/55
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population, it might or might not be in LD with the inves-
tigated SNPs.
Finally, 3'UTRs of many protein-coding genes are found
to be targets for miRNAs, short RNAs that regulate repres-
sion of translation. According to the miRNA database
[42], ERβ can be a target for a number of miRNAs. How-
ever, none of them corresponds to the 3'UTR sequences
where the SNPs in focus are located, although such miR-
NAs may exist, but remain to be identified.
Conclusion
In summary, we have demonstrated a significant differ-
ence in allelic expression of rs4986938, but not of
rs928554, in breast tumor tissues from heterozygous indi-
viduals. Our studies do not support the hypothesis that
the two commonly studied ERβ SNPs change estrogen sig-
naling by affecting ERβ mRNA stability or protein translat-
ability. Combined, our results suggest that the observed
associations between ERβ 3'UTR SNPs and disease suscep-
tibility are due to LD with another gene variant effecting
mRNA levels.
ERβ 3'UTR mRNA stability in HEK293 cells Figure 4
ERβ 3'UTR mRNA stability in HEK293 cells. The cells were transfected with 10 μg of the respective luciferase plasmids 
(ERβpromPGL3ERβ1UTRG/A for rs4986938, and ERβpromPGL3ERβ2UTRG/A for rs928554) at 90-95% confluence in 10-cm 
dishes. Twenty-four hours after transfection, cells were split into 6-well plates (6 wells/samples for each construct in total, cor-
responding to triplicate assays at two time points), so that each well could receive the same amount of plasmid. Twenty-four 
hours later, cells were treated with 1 μg/ml actinomycin D to suppress transcription. Cells were harvested 0 and 24 h after 
actinomycin D treatment, with triplicate samples for each time point. The whole experiment was performed twice, with repro-
ducible results. One representative experiment is shown. Data are shown as mean ± SD, normalized to 18s, with the 0 h time 
point set to 100%. A. ERβ1 3'UTR polymorphism (rs4986938 G↔A); B. ERβ2 polymorphism (rs928554 G↔A).
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